Great Lakes Advisors LLC Invests $3.56 Million in Vaxcyte, Inc. (NASDAQ:PCVX)

Great Lakes Advisors LLC acquired a new position in shares of Vaxcyte, Inc. (NASDAQ:PCVX - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 43,466 shares of the company's stock, valued at approximately $3,558,000.

Several other large investors also recently modified their holdings of PCVX. Janus Henderson Group PLC grew its position in shares of Vaxcyte by 23.1% during the 3rd quarter. Janus Henderson Group PLC now owns 10,921,896 shares of the company's stock worth $1,247,954,000 after buying an additional 2,052,989 shares during the period. RA Capital Management L.P. grew its position in shares of Vaxcyte by 5.9% during the 3rd quarter. RA Capital Management L.P. now owns 8,689,190 shares of the company's stock worth $992,914,000 after buying an additional 485,436 shares during the period. Charles Schwab Investment Management Inc. grew its position in shares of Vaxcyte by 47.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,295,837 shares of the company's stock worth $148,075,000 after buying an additional 419,600 shares during the period. Point72 Asset Management L.P. acquired a new stake in shares of Vaxcyte during the 3rd quarter worth approximately $41,114,000. Finally, Franklin Resources Inc. grew its position in Vaxcyte by 13.2% in the 3rd quarter. Franklin Resources Inc. now owns 2,786,335 shares of the company's stock valued at $315,162,000 after purchasing an additional 324,560 shares during the period. Institutional investors and hedge funds own 96.78% of the company's stock.

Analysts Set New Price Targets

PCVX has been the subject of several research reports. Needham & Company LLC reissued a "buy" rating and issued a $140.00 price target on shares of Vaxcyte in a research report on Wednesday, February 26th. The Goldman Sachs Group initiated coverage on shares of Vaxcyte in a research report on Friday, December 20th. They issued a "buy" rating and a $135.00 price target for the company. Finally, Guggenheim reissued a "buy" rating and issued a $160.00 price target on shares of Vaxcyte in a research report on Wednesday, March 12th. Nine analysts have rated the stock with a buy rating, According to MarketBeat, Vaxcyte presently has a consensus rating of "Buy" and a consensus price target of $147.50.

Remove Ads

Insider Buying and Selling at Vaxcyte

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the firm's stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $86.51, for a total transaction of $692,080.00. Following the transaction, the chief financial officer now directly owns 109,491 shares in the company, valued at approximately $9,472,066.41. This trade represents a 6.81 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. The trade was a 46.55 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 46,250 shares of company stock worth $3,840,018. Corporate insiders own 3.10% of the company's stock.

Vaxcyte Stock Up 1.9 %

NASDAQ:PCVX traded up $1.42 during trading hours on Wednesday, hitting $76.14. 996,528 shares of the company traded hands, compared to its average volume of 1,162,602. The firm's 50-day simple moving average is $81.77 and its 200-day simple moving average is $94.41. Vaxcyte, Inc. has a one year low of $58.10 and a one year high of $121.06. The company has a market cap of $9.80 billion, a PE ratio of -16.55 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX - Get Free Report) last issued its quarterly earnings data on Tuesday, February 25th. The company reported ($1.02) earnings per share for the quarter, beating the consensus estimate of ($1.16) by $0.14. As a group, equities research analysts expect that Vaxcyte, Inc. will post -4.21 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.